Vijay Kumar

List of Publications by Year in descending order

89 papers	6,158 citations	212478 28 h-index	87275 74 g-index
91 all docs	91 docs citations	91 times ranked	10199 citing authors

#	Article	IF	Citations
1	Extracellular vesicles in obesity and its associated inflammation. International Reviews of Immunology, 2022, 41, 30-44.	1.5	12
2	Innate lymphoid cells in autoimmune diseases. , 2022, , 143-175.		2
3	Toll-Like Receptors (TLRs) in Health and Disease: An Overview. Handbook of Experimental Pharmacology, 2022, , 1-21.	0.9	12
4	How could we forget immunometabolism in SARS-CoV2 infection or COVID-19?. International Reviews of Immunology, 2021, 40, 72-107.	1.5	33
5	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. International Reviews of Immunology, 2021, 40, 5-53.	1.5	20
6	Innate Lymphoid Cells and Adaptive Immune Cells Cross-Talk: A Secret Talk Revealed in Immune Homeostasis and Different Inflammatory Conditions. International Reviews of Immunology, 2021, 40, 217-251.	1.5	6
7	Liver X Receptor Activation with an Intranasal Polymer Therapeutic Prevents Cognitive Decline without Altering Lipid Levels. ACS Nano, 2021, 15, 4678-4687.	7.3	17
8	Can proteomics-based approaches further help COVID-19 prevention and therapy?. Expert Review of Proteomics, 2021, 18, 241-245.	1.3	5
9	High Fat Diet-Induced CD8+ T Cells in Adipose Tissue Mediate Macrophages to Sustain Low-Grade Chronic Inflammation. Frontiers in Immunology, 2021, 12, 680944.	2.2	29
10	Differential Expression of microRNAs Correlates With the Severity of Experimental Autoimmune Cystitis. Frontiers in Immunology, 2021, 12, 716564.	2.2	1
11	Immunomodulation and Biomaterials: Key Players to Repair Volumetric Muscle Loss. Cells, 2021, 10, 2016.	1.8	8
12	Going, Toll-like receptors in skin inflammation and inflammatory diseases. EXCLI Journal, 2021, 20, 52-79.	0.5	10
13	Toll-Like Receptors in Adaptive Immunity. Handbook of Experimental Pharmacology, 2021, , 95-131.	0.9	16
14	Sepsis roadmap: What we know, what we learned, and where we are going. Clinical Immunology, 2020, 210, 108264.	1.4	33
15	Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. International Immunopharmacology, 2020, 89, 107087.	1.7	109
16	Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury. Frontiers in Immunology, 2020, 11, 1722.	2.2	283
17	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. International Immunopharmacology, 2020, 88, 106980.	1.7	31
18	Innate lymphoid cell and adaptive immune cell cross-talk: A talk meant not to forget. Journal of Leukocyte Biology, 2020, 108, 397-417.	1.5	11

#	Article	IF	Citations
19	Phagocytosis: Phenotypically Simple Yet a Mechanistically Complex Process. International Reviews of Immunology, 2020, 39, 118-150.	1.5	16
20	The Trinity of cGAS, TLR9, and ALRs Guardians of the Cellular Galaxy Against Host-Derived Self-DNA. Frontiers in Immunology, 2020, 11, 624597.	2.2	40
21	Identification of a novel biomarker for pyridoxineâ€dependent epilepsy: Implications for newborn screening. Journal of Inherited Metabolic Disease, 2019, 42, 565-574.	1.7	32
22	A systems genomics approach identifies SIGLEC15 as a susceptibility factor in recurrent vulvovaginal candidiasis. Science Translational Medicine, 2019, 11, .	5.8	38
23	The complement system, toll-like receptors and inflammasomes in host defense: three musketeersâ€™ one target. International Reviews of Immunology, 2019, 38, 131-156.	1.5	30
24	Inflammation research sails through the sea of immunology to reach immunometabolism. International Immunopharmacology, 2019, 73, 128-145.	1.7	27
25	A STING to inflammation and autoimmunity. Journal of Leukocyte Biology, 2019, 106, 171-185.	1.5	75
26	Toll-like receptors in the pathogenesis of neuroinflammation. Journal of Neuroimmunology, 2019, 332, 16-30.	1.1	223
27	Lipopolysaccharide-acylating capacity of the gut microbiota and its potential impact on the immunopathogenesis of HIV infection. Aids, 2019, 33, 753-755.	1.0	1
28	Natural killer cells in sepsis: Underprivileged innate immune cells. European Journal of Cell Biology, 2019, 98, 81-93.	1.6	33
29	Immunometabolism: Another Road to Sepsis and Its Therapeutic Targeting. Inflammation, 2019, 42, 765-788.	1.7	40
30	Targeting macrophage immunometabolism: Dawn in the darkness of sepsis. International Immunopharmacology, 2018, 58, 173-185.	1.7	98
31	T cells and their immunometabolism: A novel way to understanding sepsis immunopathogenesis and future therapeutics. European Journal of Cell Biology, 2018, 97, 379-392.	1.6	72
32	Role of MAIT cells in the immunopathogenesis of inflammatory diseases: New players in old game. International Reviews of Immunology, 2018, 37, 90-110.	1.5	27
33	Inflammasomes: Pandora’s box for sepsis. Journal of Inflammation Research, 2018, Volume 11, 477-502.	1.6	61
34	Dendritic cells in sepsis: Potential immunoregulatory cells with therapeutic potential. Molecular Immunology, 2018, 101, 615-626.	1.0	33
35	Regenerated cellulose capsules for controlled drug delivery: Part IV. In-vitro evaluation of novel self-pore forming regenerated cellulose capsules. European Journal of Pharmaceutical Sciences, 2017, 97, 227-236.	1.9	6
36	Prenatal exposure estimation of BPA and DEHP using integrated external and internal dosimetry: A case study. Environmental Research, 2017, 158, 566-575.	3.7	39

#	Article	IF	Citations
37	Targeting calpains: A novel immunomodulatory approach for microbial infections. European Journal of Pharmacology, 2017, 814, 28-44.	1.7	8
38	A prospective cohort study of the silk fibroin patch in chronic tympanic membrane perforation. Laryngoscope, 2016, 126, 2798-2803.	1.1	22
39	ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6669-E6678.	3.3	82
40	Regenerated cellulose capsules for controlled drug delivery: Part III. Developing a fabrication method and evaluating extemporaneous utility for controlled-release. European Journal of Pharmaceutical Sciences, 2016, 91, 40-49.	1.9	6
41	Regenerated Cellulose Capsules for Controlled Drug Delivery, Part 2: Modulating Membrane Permeability by Incorporation of Depolymerized Cellulose and Altering Membrane Thickness. Journal of Pharmaceutical Sciences, 2015, 104, 4266-4275.	1.6	7
42	The RIG-I-like helicase receptor MDA5 (IFIH1) is involved in the host defense against Candida infections. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 963-974.	1.3	69
43	Tyrosine Kinase Inhibition in Leukemia Induces an Altered Metabolic State Sensitive to Mitochondrial Perturbations. Clinical Cancer Research, 2015, 21, 1360-1372.	3.2	58
44	HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1. Genes and Immunity, 2015, 16, 247-252.	2.2	96
45	Regenerated cellulose capsules for controlled drug delivery: Part I. Physiological characteristics of membrane formation and the influence of thermal annealing. Cellulose, 2015, 22, 3237-3250.	2.4	5
46	Calpains promote neutrophil recruitment and bacterial clearance in an acute bacterial peritonitis model. European Journal of Immunology, 2014, 44, 831-841.	1.6	20
47	Innate Lymphoid Cells: Immunoregulatory Cells of Mucosal Inflammation. European Journal of Inflammation, 2014, 12, 11-20.	0.2	13
48	Innate lymphoid cells: New paradigm in immunology of inflammation. Immunology Letters, 2014, 157, 23-37.	1.1	46
49	Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science, 2014, 345, 1251086.	6.0	1,338
50	mTOR- and HIF-1Î±â€“mediated aerobic glycolysis as metabolic basis for trained immunity. Science, 2014, 345, 1250684.	6.0	1,517
51	Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?. Purinergic Signalling, 2013, 9, 145-165.	1.1	89
52	Genome-wide Association Study Signal at the 12q12 Locus for Crohnâ€™s Disease May Represent Associations with the MUC19 Gene. Inflammatory Bowel Diseases, 2013, 19, 1254-1259.	0.9	21
53	Receptor dependent immobilization of spermatozoa by sperm immobilization factor isolated from Escherichia coli: Proof of evidence. International Journal of Urology, 2011, 18, 597-603.	0.5	14
54	Pharmacokinetics of cefpodoxime in plasma and subcutaneous fluid following oral administration of cefpodoxime proxetil in male beagle dogs. Journal of Veterinary Pharmacology and Therapeutics, 2011, 34, 130-135.	0.6	11

#	Article	IF	Citations
55	Acute Lung Inflammation in Klebsiella pneumoniae B5055-Induced Pneumonia and Sepsis in BALB/c Mice: A Comparative Study. Inflammation, 2011, 34, 452-462.	1.7	19
56	Thalidomide: An Old Drug with New Action. Journal of Chemotherapy, 2011, 23, 326-334.	0.7	29
57	Mast cells: Emerging sentinel innate immune cells with diverse role in immunity. Molecular Immunology, 2010, 48, 14-25.	1.0	81
58	2-Chloroadenosine (2-CADO) treatment modulates the pro-inflammatory immune response to prevent acute lung inflammation in BALB/c mice suffering from Klebsiella pneumoniae B5055-induced pneumonia. International Journal of Antimicrobial Agents, 2010, 35, 599-602.	1.1	5
59	Is neuroimmunomodulation a future therapeutic approach for sepsis?. International Immunopharmacology, 2010, 10, 9-17.	1.7	39
60	Thalidomide treatment modulates macrophage pro-inflammatory function and cytokine levels in Klebsiella pneumoniae B5055 induced pneumonia in BALB/c mice. International Immunopharmacology, 2010, 10, 777-783.	1.7	19
61	Neutrophils: Cinderella of innate immune system. International Immunopharmacology, 2010, 10, 1325-1334.	1.7	343
62	A Combination of Thalidomide and Augmentin Protects BALB/c Mice Suffering fromKlebsiella pneumoniaeB5055-Induced Sepsis. Journal of Chemotherapy, 2009, 21, 159-164.	0.7	6
63	Adenosine: An endogenous modulator of innate immune system with therapeutic potential. European Journal of Pharmacology, 2009, 616, 7-15.	1.7	156
64	Intravenous 2-Chloroadenosine Protects BALB/C Mice fromKlebsiella pneumoniaeB5055-Induced Sepsis by Modulating the Pro-Inflammatory Immune Response. Journal of Chemotherapy, 2009, 21, 639-645.	0.7	2
65	Impact of the impact factor in biomedical research: its use and misuse. Singapore Medical Journal, 2009, 50, 752-5.	0.3	26
66	Anti-inflammatory effect of thalidomide alone or in combination with augmentin in Klebsiella pneumoniae B5055 induced acute lung infection in BALB/c mice. European Journal of Pharmacology, 2008, 592, 146-150.	1.7	11
67	Protective potential of 2-chloroadenosine in Klebsiella pneumoniae B5055 induced sepsis in BALB/c mice. Critical Care, 2008, 12, P2.	2.5	1
68	Effect of Clarithromycin on Lung Inflammation and Alveolar Macrophage Function inKlebsiella pneumoniaeB5055-Induced Acute Lung Infection in BALB/c mice. Journal of Chemotherapy, 2008, 20, 609-614.	0.7	9
69	Innate Immunity in Sepsis Pathogenesis and Its Modulation: New Immunomodulatory Targets Revealed. Journal of Chemotherapy, 2008, 20, 672-683.	0.7	29
70	Genetic basis of HIV-1 resistance and susceptibility: an approach to understand correlation between human genes and HIV-1 infection. Indian Journal of Experimental Biology, 2006, 44, 683-92.	0.5	4
71	Study of the influence of reaction conditions on the degree of substitution, intrinsic viscosity, and yield of oxidized cellulose acetate by factorial experimental design. Journal of Applied Polymer Science, 2005, 96, 696-705.	1.3	1
72	Radiolabeled white blood cells and direct targeting of micro-organisms for infection imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2005, 49, 325-38.	0.4	21

#	Article	IF	Citations
73	Oxidized cellulose esters: I. Preparation and characterization of oxidized cellulose acetates â€" a new class of biodegradable polymers. Journal of Biomaterials Science, Polymer Edition, 2002, 13, 273-286.	1.9	7
74	Preparation, characterization, and tabletting properties of a new cellulose-based pharmaceutical aid. International Journal of Pharmaceutics, 2002, 235, 129-140.	2.6	107
75	Preparation and Characterization of Spray-Dried Oxidized Cellulose Microparticles. Pharmaceutical Development and Technology, 2001, 6, 449-458.	1.1	14
76	Improved Dissolution and Cytotoxicity of Camptothecin Incorporated into Oxidized-Cellulose Microspheres Prepared by Spray Drying. Pharmaceutical Development and Technology, 2001, 6, 459-467.	1.1	21
77	NONCOVALENT IMMOBILIZATION OF BOVINE SERUM ALBUMIN ON OXIDIZED CELLULOSE. Artificial Cells, Blood Substitutes, and Biotechnology, 2001, 29, 203-212.	0.9	12
78	Effect of the agitation rate on the generation of low-crystallinity cellulose from phosphoric acid. Journal of Applied Polymer Science, 2001, 82, 2624-2628.	1.3	15
79	Compression, compaction, and disintegration properties of low crystallinity celluloses produced using different agitation rates during their regeneration from phosphoric acid solutions. AAPS PharmSciTech, 2001, 2, 22-28.	1.5	36
80	Interpolymer Complexation. II. Entrapment of Ibuprofen by In-Situ Complexation Between Polyvinyl Acetate Phthalate (PVAP) and Polyvinylpyrrolidone (PVP) and Development of a Chewable Tablet Formulation. Pharmaceutical Development and Technology, 2001, 6, 71-81.	1.1	8
81	Extended TIP(P) Analogues as Precursors for Labeled Î´-Opioid Receptor Ligands. Journal of Medicinal Chemistry, 2000, 43, 5050-5054.	2.9	9
82	Analysis of carboxyl content in oxidized celluloses by solid-state 13C CP/MAS NMR spectroscopy. International Journal of Pharmaceutics, 1999, 184, 219-226.	2.6	37
83	Interpolymer complexation. I. Preparation and characterization of a polyvinyl acetate phthalate-polyvinylpyrrolidone (PVAP-PVP) complex. International Journal of Pharmaceutics, 1999, 188, 221-232.	2.6	38
84	Chemically-Modified Celldlosic Polymers. Drug Development and Industrial Pharmacy, 1993, 19, 1-31.	0.9	49
85	Comparison of Commercial Kits for the Detection of Anti-nDNA Antibodies Using Crithidia luciliae. American Journal of Clinical Pathology, 1987, 87, 461-469.	0.4	9
86	Innate Immune System in Sepsis Immunopathogenesis and Its Modulation as a Future Therapeutic Approach. , 0, , .		0
87	Macrophages: The Potent Immunoregulatory Innate Immune Cells. , 0, , .		28
88	Learning from Bats to Escape from Potent or Severe Viral Infections. , 0, , .		4
89	Introductory Chapter: The Journey of Inflammation and Inflammatory Disease Research - Past, Present, and Future. , 0, , .		0